KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Non-Current Debt: 2012-2025

Historic Non-Current Debt for Halozyme Therapeutics (HALO) over the last 3 years, with Sep 2025 value amounting to $800.1 million.

  • Halozyme Therapeutics' Non-Current Debt fell 46.81% to $800.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $800.1 million, marking a year-over-year decrease of 46.81%. This contributed to the annual value of $1.5 billion for FY2024, which is 0.44% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Non-Current Debt stood at $800.1 million for Q3 2025, which was down 46.98% from $1.5 billion recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Non-Current Debt ranged from a high of $1.5 billion in Q2 2025 and a low of $787.3 million during Q4 2021.
  • In the last 3 years, Halozyme Therapeutics' Non-Current Debt had a median value of $1.5 billion in 2024 and averaged $1.4 billion.
  • In the last 5 years, Halozyme Therapeutics' Non-Current Debt spiked by 89.62% in 2022 and then plummeted by 46.81% in 2025.
  • Quarterly analysis of 5 years shows Halozyme Therapeutics' Non-Current Debt stood at $787.3 million in 2021, then spiked by 89.62% to $1.5 billion in 2022, then increased by 0.43% to $1.5 billion in 2023, then rose by 0.44% to $1.5 billion in 2024, then tumbled by 46.81% to $800.1 million in 2025.
  • Its last three reported values are $800.1 million in Q3 2025, $1.5 billion for Q2 2025, and $1.5 billion during Q1 2025.